Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Obecabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Obecabtagene autoleucel overview

Obecabtagene autoleucel is under development for the treatment of relapsed or refractory CD19 positive acute lymphoblastic leukemia in adults and pediatrics, diffuse large B cell lymphoma, systemic lupus erythematosus, B-cell acute lymphoblastic leukaemia, chronic lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, primary CNS lymphoma, Burkitt lymphoma and primary mediastinal large B-cell lymphoma. It is administered as an intravenous infusion. The therapeutic candidate constitutes patient's own T cells transduced with lentiviral vector that have been genetically modified to express CD19CAT-41BBZ targeting CD19. It was under development for the treatment of marginal zone lymphoma.

Autolus Therapeutics overview

Autolus Therapeutics (Autolus) is a clinical-stage biopharmaceutical company. It offers programmed T-cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products include Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. The company applies its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products as it is both safe and the most therapeutically effective approach to manufacturing CAR T cells. Autolus is headquartered in London, England, the UK.

For a complete picture of Obecabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.